Beam Therapeutics Inc. (BEAM)
| Market Cap | 2.97B +85.1% |
| Revenue (ttm) | 156.04M +158.9% |
| Net Income | -86.52M |
| EPS | -0.84 |
| Shares Out | 99.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,153,291 |
| Open | 28.74 |
| Previous Close | 28.39 |
| Day's Range | 28.61 - 30.50 |
| 52-Week Range | 15.60 - 38.26 |
| Beta | 2.21 |
| Analysts | Strong Buy |
| Price Target | 52.15 (+75.24%) |
| Earnings Date | Aug 4, 2026 |
About BEAM
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylk... [Read more]
Financial Performance
In 2025, Beam Therapeutics's revenue was $139.74 million, an increase of 120.01% compared to the previous year's $63.52 million. Losses were -$79.99 million, -78.77% less than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for BEAM stock is "Strong Buy." The 12-month stock price target is $52.15, which is an increase of 75.24% from the latest price.
News
Beam Therapeutics price target lowered to $43 from $47 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on Beam Therapeutics (BEAM) to $43 from $47 and keeps a Buy rating on the shares. The firm adjusted targets for…
Beam Therapeutics price target raised to $78 from $75 at Canaccord
Canaccord raised the firm’s price target on Beam Therapeutics (BEAM) to $78 from $75 and keeps a Buy rating on the shares. The firm updated its model and said 2Q26…
Beam Therapeutics reports Q2 EPS ($1.18), consensus ($1.13)
“The second quarter marked another period of rapid progress and disciplined execution on the clinical, regulatory and operational milestones we set for Beam,” said John Evans, chief executive officer ...
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
Beam Therapeutics Earnings release: Q2 2026
Beam Therapeutics released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Beam Therapeutics Quarterly report: Q2 2026
Beam Therapeutics has published its Q2 2026 quarterly earnings report on August 4, 2026.
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the...
Beam Therapeutics Slides: Conference presentation
Beam Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 9, 2026.
TD Cowen says arbitration decision removes overhang for Prime Medicine’s PM647
TD Cowen notes that Prime Medicine (PRME) announced a positive binding arbitration resolution with Beam Therapeutics (BEAM) over PM647 in alpha-1 antitrypsin deficiency, confirming PM647 is in Prime’s...
Resolution in favor of Prime has limited impact to Beam, says BofA
BofA analyst Alec Stranahan reiterated a Buy rating and $47 price target on Beam Therapeutics (BEAM) after Prime Medicine (PRME) announced a “positive” resolution to arbitration with Beam Therapeutics...
Prime Medicine reports positive resolution to arbitration with Beam Therapeutics
Prime Medicine (PRME) earlier announced a positive, binding resolution of its previously disclosed arbitration with Beam Therapeutics (BEAM) relating to the parties’ 2019 Collaboration and License Agr...
Beam Therapeutics announces U.S. FDA clearned IND application for BEAM-304
Beam Therapeutics (BEAM) announced that the United States Food and Drug Administration, FDA, has cleared the investigational new drug, IND, application for BEAM-304 for the treatment of phenylketonuri...
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration
BEAM-304 Development Approach Has Potential to Create Transformative, One-time Therapies for the Majority of Patients with PKU BEAM-304 Program Designed as Platform-based Approach Reflecting Emerging...
Beam Therapeutics Transcript: AGM 2026
The meeting featured the election of three directors, ratification of Deloitte as auditor, and approval of executive compensation, with all proposals passing. No shareholder questions were raised, and final vote results will be filed in a Form 8-K.
Beam Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
Base editing programs show strong efficacy and safety in hematology and liver diseases, with lead assets advancing toward regulatory filings and broader patient reach. Accelerated approval is supported by robust biomarker data, and pricing will reflect long-term value.
Beam Therapeutics presents Phase 1/2 data for BEAM-302
Beam Therapeutics (BEAM) presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency at a symposium on translating scientific discovery in gene ed...
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity Po...
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease. DURHAM, N.C.
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John...
Beam Therapeutics price target lowered to $39 from $40 at Bernstein
Bernstein analyst William Pickering lowered the firm’s price target on Beam Therapeutics (BEAM) to $39 from $40 and keeps an Outperform rating on the shares. Biotech has had a strong…
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the ...
Beam Therapeutics reports Q1 EPS (91c), consensus ($1.01)
Reports Q1 revenue $31.74M, consensus $12.22M. “The first quarter of 2026 was a defining period for Beam, marked by meaningful clinical advances across our portfolio and key steps toward becoming…
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort ...
Beam Therapeutics Earnings release: Q1 2026
Beam Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.